Embryonic Structure

Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides

1 month ago1 month ago talkbio0Tagged Adverse event, ANGPTL4 gene, Antibodies, Dosage, Embryonic remnant, Hypertriglyceridemia, MAR001, MAR001[1, Phase 2a clinical trial, placebo-adjusted mean reduction, Positive

MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1

Rallybio Halts Development of Lead FNAIT Program Following Phase 2 Failure

2 months ago talkbio0Tagged Alloimmune thrombocytopenia, Biotech pipeline shift, Fetal and neonatal alloimmune thrombocytopenia, Fetus, immune disorder therapy, Infant, Newborn, Mother (person), Phase 2 clinical trial, Rallybio RLYB212

Rallybio RLYB212, Fetal and neonatal alloimmune thrombocytopenia (FNAIT), Phase 2 clinical trial, Maternal immune disorder therapy, Biotech pipeline shift

Mesoblast Secures FDA Approval for Ryoncil, First Mesenchymal Stromal Cell Therapy for Pediatric Steroid-Refractory Acute Graft-Versus-Host Disease

6 months ago talkbio0Tagged Approved, Cell Therapy, Mesenchymal Stromal Cell Therapy, Mesoblast, Pediatric brand name, Ryoncil, SR-aGVHD, Steroid-Refractory Acute Graft-Versus-Host Disease, United States Food and Drug Administration

Mesoblast, Ryoncil, FDA Approval, Mesenchymal Stromal Cell Therapy, Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD), Pediatric Patients, Cell Therapy

EMA Recommends Halt on Preterm Birth Medications Due to Safety Concerns

1 year ago talkbio0Tagged concerns, development aspects, European Medicines Agency, Fetus, Pregnancy, Safety, Suspensions

European Medicines Agency (EMA), safety committee, preterm birth drugs, suspension, safety concerns, pregnancy, fetal development.